These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33480862)

  • 1. Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study).
    Terra L; Hooning MJ; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Mom C; van Dorst EBL; Mourits MJE; Slangen BFM; Gaarenstroom KN; Zillikens MC; Leiner T; van der Kolk L; Collee M; Wevers M; Ausems MGEM; van Engelen K; Berger LP; van Asperen CJ; Gomez-Garcia EB; van de Beek I; Rookus MA; Hauptmann M; Bleiker EM; Schagen SB; Aaronson NK; Maas AHEM; van Leeuwen FE
    JMIR Res Protoc; 2021 Jan; 10(1):e24414. PubMed ID: 33480862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
    Steenbeek MP; Harmsen MG; Hoogerbrugge N; de Jong MA; Maas AHEM; Prins JB; Bulten J; Teerenstra S; van Bommel MHD; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JMJ; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Massuger LFAG; IntHout J; Hermens RPMG; de Hullu JA
    JAMA Oncol; 2021 Aug; 7(8):1203-1212. PubMed ID: 34081085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on cognition in women with high familial risk of ovarian cancer: A cross-sectional study.
    Terra L; Lee Meeuw Kjoe PR; Agelink van Rentergem JA; Beekman MJ; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Mourits MJE; van Dorst EBL; Mom CH; Slangen BFM; Gaarenstroom KN; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; van der Wall E; van Leeuwen FE; Schagen SB
    BJOG; 2023 Jul; 130(8):968-977. PubMed ID: 36715559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study.
    Mai PL; Huang HQ; Wenzel LB; Han PK; Moser RP; Rodriguez GC; Boggess J; Rutherford TJ; Cohn DE; Kauff ND; Phillips KA; Wilkinson K; Wenham RM; Hamilton C; Powell MA; Walker JL; Greene MH; Hensley ML
    Gynecol Oncol; 2020 Jan; 156(1):131-139. PubMed ID: 31759774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severity and duration of menopausal symptoms after risk-reducing salpingo-oophorectomy.
    Stuursma A; van Driel CMG; Wessels NJ; de Bock GH; Mourits MJE
    Maturitas; 2018 May; 111():69-76. PubMed ID: 29673834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
    Mavaddat N; Antoniou AC; Mooij TM; Hooning MJ; Heemskerk-Gerritsen BA; ; Noguès C; Gauthier-Villars M; Caron O; Gesta P; Pujol P; Lortholary A; ; Barrowdale D; Frost D; Evans DG; Izatt L; Adlard J; Eeles R; Brewer C; Tischkowitz M; Henderson A; Cook J; Eccles D; ; van Engelen K; Mourits MJE; Ausems MGEM; Koppert LB; Hopper JL; John EM; Chung WK; Andrulis IL; Daly MB; Buys SS; ; Benitez J; Caldes T; Jakubowska A; Simard J; Singer CF; Tan Y; Olah E; Navratilova M; Foretova L; Gerdes AM; Roos-Blom MJ; Van Leeuwen FE; Arver B; Olsson H; Schmutzler RK; Engel C; Kast K; Phillips KA; Terry MB; Milne RL; Goldgar DE; Rookus MA; Andrieu N; Easton DF; ; ;
    Breast Cancer Res; 2020 Jan; 22(1):8. PubMed ID: 31948486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy.
    Teixeira N; Mourits MJ; Oosterwijk JC; Fakkert IE; Absalom AR; Bakker SJL; van der Meer P; de Bock GH
    Fam Cancer; 2019 Jan; 18(1):19-27. PubMed ID: 29881922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer.
    Fakkert IE; Abma EM; Westrik IG; Lefrandt JD; Wolffenbuttel BH; Oosterwijk JC; Slart RH; van der Veer E; de Bock GH; Mourits MJ
    Eur J Cancer; 2015 Feb; 51(3):400-8. PubMed ID: 25532426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The consequences of risk reducing salpingo-oophorectomy: the case for a coordinated approach to long-term follow up post surgical menopause.
    Pezaro C; James P; McKinley J; Shanahan M; Young MA; Mitchell G
    Fam Cancer; 2012 Sep; 11(3):403-10. PubMed ID: 22477030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.
    Harmsen MG; Arts-de Jong M; Hoogerbrugge N; Maas AH; Prins JB; Bulten J; Teerenstra S; Adang EM; Piek JM; van Doorn HC; van Beurden M; Mourits MJ; Zweemer RP; Gaarenstroom KN; Slangen BF; Vos MC; van Lonkhuijzen LR; Massuger LF; Hermens RP; de Hullu JA
    BMC Cancer; 2015 Aug; 15():593. PubMed ID: 26286255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
    Stjepanovic N; Villacampa G; Nead KT; Torres-Esquius S; Melis GG; Nathanson KL; Teule A; Brunet J; Y Cajal TR; Llort G; Dienstmann R; Rue M; Domchek SM; Balmaña J
    Eur J Cancer; 2020 Jun; 132():53-60. PubMed ID: 32325420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sexual function, menopausal symptoms, depression and cancer worry in women with BRCA mutations.
    Powell CB; Alabaster A; Le A; Stoller N; Armstrong MA; Raine-Bennett T
    Psychooncology; 2020 Feb; 29(2):331-338. PubMed ID: 31654466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer.
    Michelsen TM; Dørum A; Tropé CG; Fosså SD; Dahl AA
    Int J Gynecol Cancer; 2009 Aug; 19(6):1029-36. PubMed ID: 19820364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term impact of surgically induced menopause on cognitive function and wellbeing in women at high risk for ovarian cancer following risk-reducing bilateral salpingo-oophorectomy.
    Chang H; Kamara D; Bresee C; Lester J; Cass I
    Menopause; 2020 Dec; 28(4):354-359. PubMed ID: 33350669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study.
    Gaba F; Blyuss O; Chandrasekaran D; Osman M; Goyal S; Gan C; Izatt L; Tripathi V; Esteban I; McNicol L; Ragupathy K; Crawford R; Evans DG; Legood R; Menon U; Manchanda R
    BJOG; 2021 Mar; 128(4):714-726. PubMed ID: 32803845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life after risk-reducing surgery for breast and ovarian cancer prevention: a systematic review and meta-analysis.
    Wei X; Oxley S; Sideris M; Kalra A; Brentnall A; Sun L; Yang L; Legood R; Manchanda R
    Am J Obstet Gynecol; 2023 Oct; 229(4):388-409.e4. PubMed ID: 37059410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does anti-Müllerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy? A prospective observational study.
    Vermeulen RFM; van Beurden M; Gaarenstroom KN; Teunis T; Kieffer JM; Aaronson NK; Kenter GG; Korse CM
    Climacteric; 2018 Dec; 21(6):574-580. PubMed ID: 30295077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis.
    Manchanda R; Legood R; Antoniou AC; Gordeev VS; Menon U
    J Med Genet; 2016 Sep; 53(9):591-9. PubMed ID: 27354448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No signs of subclinical atherosclerosis after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers.
    van Bommel MHD; de Jong MA; Steenbeek MP; Bots ML; van Westerop LLM; Hopman MTE; Hoogerbrugge N; de Hullu JA; Maas AHEM
    J Cardiol; 2021 Jun; 77(6):570-575. PubMed ID: 33229237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.